# Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

> **NCT03772132** · PHASE2 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 100 (estimated)

## Conditions studied

- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Gallbladder Cancer

## Interventions

- **BIOLOGICAL:** mutation and signal pathway activation status analysis Drug: FORFIRINOX

## Key facts

- **NCT ID:** NCT03772132
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-12-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772132, "Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03772132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*